Esperion Therapeutics (ESPR) Change in Account Payables (2012 - 2026)

Esperion Therapeutics' Change in Account Payables history runs 15 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• Quarterly Change in Account Payables fell 88.01% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.6 million (down 108.21% YoY) and the FY2025 annual result came in at $20.9 million, up 68.26% from the prior year.
• Change in Account Payables was $3.3 million for Q1 2026 at Esperion Therapeutics, up from -$12.4 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $27.8 million in Q1 2025 and bottomed at -$14.0 million in Q2 2022.
• A 5-year average of $3.0 million and a median of $3.3 million in 2026 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables plunged 2242.74% — and 2025, when it soared 907.07%.
• Esperion Therapeutics' Change in Account Payables stood at $4.5 million in 2022, then increased by 23.02% to $5.5 million in 2023, then jumped by 69.04% to $9.3 million in 2024, then tumbled by 233.76% to -$12.4 million in 2025, then jumped by 126.82% to $3.3 million in 2026.
• Business Quant data shows ESPR's Change in Account Payables at $3.3 million in Q1 2026, -$12.4 million in Q4 2025, and $2.9 million in Q3 2025.